Opioid-Induced Androgen Deficiency (OPIAD)
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Opioid therapy is one of the most effective forms of analgesia currently in use. In the past few decades, the use of opioids as a long-term treatment for chronic pain has increased dramatically. Accompanying this upsurge in the use of long-term opioid therapy has been an increase in the occurrence of opioid associated endocrinopathy, most commonly manifested as an androgen deficiency and therefore referred to as opioid associated androgen deficiency (OPIAD). This syndrome is characterized by the presence of inappropriately low levels of gonadotropins (follicle stimulating hormone and luteinizing hormone) leading to inadequate production of sex hormones, particularly testosterone. Symptoms that may manifest in patients with OPIAD include reduced libido, erectile dysfunction, fatigue, hot flashes, and depression. Physical findings may include reduced facial and body hair, anemia, decreased muscle mass, weight gain, and osteopenia or osteoporosis. Additionally, both men and women with OPIAD may suffer from infertility. While the literature regarding OPIAD remains limited, it is apparent that OPIAD is becoming increasingly prevalent among chronic opioid consumers but often goes unrecognized. OPIAD can have a significant negative impact on the the quality of life of opioid users, and clinicians should anticipate the potential for its occurrence whenever long-term opioid prescribing is undertaken. Once diagnosed, treatment for OPIAD may be offered utilizing a number of androgen replacement therapy options including a variety of testosterone preparations and, for female patients with OPIAD, dehydroepiandrosterone (DHEA) supplementation. Follow-up evaluation of patients receiving androgen replacement therapy should include a review of any unresolved symptoms of hypogonadism, laboratory evaluation, and surveillance for potential adverse effects of androgen replacement therapy including prostate disease in males. Key words: Opioid, hypogonadism, testosterone, endocrine, androgen
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713
Validation of a screening questionnaire for androgen deficiency in aging males
Morley, J. E., Charlton, E., Patrick, P., Kaiser, F. E., Cadeau, P., McCready, D., & Perry, H. M. (2000) · Metabolism · doi:10.1053/meta.2000.8625 · Cited by 662
Endocrine consequences of long-term intrathecal administration of opioids
Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J.-P., Opsomer, F., Adriaensen, H., Verlooy, J., Van Havenbergh, T., Smet, M., & Van Acker, K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6615 · Cited by 491
Hypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401
Fink, H. A., Ewing, S. K., Ensrud, K. E., Barrett-Connor, E., Taylor, B. C., Cauley, J. A., & Orwoll, E. S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0173 · Cited by 319
The impact of opioids on the endocrine system
Katz, N., & Mazer, N. A. (2009) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181850df6 · Cited by 307
Androgen therapy in women: An Endocrine Society clinical practice guideline
Wierman, M. E., Basson, R., Davis, S. R., Khosla, S., Miller, K. K., Rosner, W., & Santoro, N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1121 · Cited by 301
Daniell, H. W. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.08.005 · Cited by 263
Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids
Rajagopal, A., Vassilopoulou‐Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. (2004) · Cancer · doi:10.1002/cncr.20028 · Cited by 206
Hypogonadism in patients treated with intrathecal morphine
Finch, P. M., Roberts, L. J., Price, L., Hadlow, N. C., & Pullan, P. T. (2000) · The Clinical Journal of Pain · doi:10.1097/00002508-200009000-00011 · Cited by 144
Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency
Daniell, H. W., Lentz, R., & Mazer, N. A. (2006) · The Journal of Pain · doi:10.1016/j.jpain.2005.10.009 · Cited by 135
Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women
Fraser, L.-A., Morrison, D., Morley-Forster, P., Paul, T., Tokmakejian, S., Larry Nicholson, R., Bureau, Y., Friedman, T., & Uum, S. H. M. V. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2008-1076715 · Cited by 112
Endocrine consequences of opioid therapy
Aloisi, A. M., Aurilio, C., Bachiocco, V., Biasi, G., Fiorenzani, P., Pace, M. C., Paci, V., Pari, G., Passavanti, G., Ravaioli, L., et al. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.013 · Cited by 107
Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients
Aloisi, A., Ceccarelli, I., Carlucci, M., Suman, A., Sindaco, G., Mameli, S., Paci, V., Ravaioli, L., Passavanti, G., Bachiocco, V., et al. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-26 · Cited by 77
Cited by
The association between chronic pain and obesity
Okifuji, A., & Hare, B. (2015) · Journal of Pain Research · doi:10.2147/jpr.s55598 · Cited by 597
Clinical Practice Guidelines for Pain Management in Acute Musculoskeletal Injury
Hsu, J. R., Mir, H., Wally, M. K., Seymour, R. B., & the Orthopaedic Trauma Association Musculoskeletal Pain Task Force (2019) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001430 · Cited by 280
Engeler, D. S., Baranowski, A. P., Dinis-Oliveira, P., Elneil, S., Hughes, J., Messelink, E. J., van Ophoven, A., & Williams, A. C. (2013) · European Urology · doi:10.1016/j.eururo.2013.04.035 · Cited by 255
Testosterone suppression in opioid users: A systematic review and meta-analysis
Bawor, M., Bami, H., Dennis, B. B., Plater, C., Worster, A., Varenbut, M., Daiter, J., Marsh, D. C., Steiner, M., Anglin, R., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.038 · Cited by 123
Depression in adolescents and young adults with cancer
Park, E. M., & Rosenstein, D. L. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/epark · Cited by 108
Metadata
- Authors
- Elliott, J. A.
- Venue
- Pain Physician
- Published
- 2012-07-14
- Volume
- 3S;15
- Issue
- 3S;7
- Pages
- ES145-ES156
- ISSN
- 1533-3159 (ISSN-L)
- 2150-1149
- OpenAlex
- W2289902531
- Cited by
- 129
- References
- 18
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.